MiMedx filed a tortuous interference lawsuit against Organogenesis, a company manufactures two skin substitute products competing with MiMedx's EpiFix allograft.
Here are seven things to know about the suit:
1. MiMedx allografts were "suddenly and unexpectedly" removed from the 65IIA Federal Supply Schedule of the Veterans Administration in June 2013.
2. MiMedx challenged the action and within a few days the VA decided MiMedx allograft removal wasn't warranted and they were full restored to FSS. The VA also sent an apology letter to MiMedx.
3. After filing a Freedom of Information Act request, MiMedx received information that Organogenesis provided "material misinformation" to the VA that caused the decision to remove MiMedx products.
4. The lawsuit alleges "Organogenesis engaged in malicious actions that tortuously interfered with MiMedx's contractual relationship selling into the VA," according to a MiMedx report.
5. MiMedx plans to pursue "any and all remedies" to address Organogenesis's actions.
6. The suit also inserts unjust enrichment.
7. The lawsuit was filed in the United States District Court for the Northern District of Georgia and damages sought were not specified.